CoinShares: Digital asset investment products saw inflows of $857.9 million last week, marking six consecutive weeks of net inflows.
Foresight News reports that a certain exchange released its latest weekly report, stating that digital asset investment products saw an inflow of $857.9 million last week, marking the sixth consecutive week of net inflows and the largest single-week inflow since April 24. The total assets under management have risen to $160 billion. Boosted by the compromise text on stablecoin yields under the CLARITY Act, Bitcoin broke through $80,000 during the week, hitting a new high since the February pullback. Among these, Bitcoin saw an inflow of $706.1 million, with a cumulative inflow of $4.9 billion so far this year; Ethereum recorded an inflow of $77.1 million, reversing last week's $81.6 million outflow; Solana saw an inflow of $47.6 million, and XRP recorded an inflow of $39.6 million. Short Bitcoin products experienced an outflow of $14.4 million, the largest single-week outflow this year, indicating that hedge positions are being closed as bullish confidence grows. Regionally, the US led this week's inflows with $776.6 million, a significant rebound from $47.5 million last week; Germany recorded an inflow of $50.6 million, Switzerland $21.1 million, and the Netherlands $5 million. Additionally, multi-asset products experienced an outflow of $5.5 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Goldman Sachs comments on AMD (AMD.US) Q3 performance: Data center CPU and GPU show strong performance, growth visibility for 2027 is clear
Goldman Sachs released a research report maintaining a "Buy" rating on AMD (AMD.US) with a 12-month target price of $675.

A recorder hidden in toilet paper exposes OpenAI's long-standing safety issues

AbbVie (ABBV.US) expands Oxford R&D facility in UK, betting on innovation in immunology, neuroscience, and oncology drugs
AbbVie announced on Wednesday that, as part of an investment plan exceeding 120 million pounds (approximately $161 million), the company has expanded its research and development facility in Oxford, United Kingdom.
